Free tool
FAERS Monitor: Sancuso
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022198 or its brand name (Sancuso, Granisetron). Reports on generic versions are filed under their own applications.
Reports
10,458
Serious
8,771
84% of reports
Hospitalization
5,106
Death reported
1,879
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea1,337
- vomiting768
- febrile neutropenia741
- diarrhoea728
- pyrexia664
- death611
- dyspnoea605
- fatigue570
- neutropenia492
- anaemia491
- off label use461
- constipation404
- product adhesion issue399
- decreased appetite381
- pneumonia376
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 129 |
| 2005 | 106 |
| 2006 | 60 |
| 2007 | 74 |
| 2008 | 63 |
| 2009 | 54 |
| 2010 | 129 |
| 2011 | 250 |
| 2012 | 626 |
| 2013 | 392 |
| 2014 | 446 |
| 2015 | 481 |
| 2016 | 829 |
| 2017 | 686 |
| 2018 | 859 |
| 2019 | 943 |
| 2020 | 871 |
| 2021 | 834 |
| 2022 | 831 |
| 2023 | 528 |
| 2024 | 461 |
| 2025 | 495 |
| 2026 | 310 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,701 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 741 | 22.7 | 21.2 | 15,233 |
| product adhesion issueSignal | 399 | 22.7 | 20.6 | 8,177 |
| neutropeniaSignal | 492 | 7.3 | 6.7 | 2,676 |
| anaemiaSignal | 491 | 5.2 | 4.8 | 1,667 |
| pyrexiaSignal | 664 | 3.9 | 3.6 | 1,428 |
| constipationSignal | 404 | 3.7 | 3.4 | 812 |
| nauseaSignal | 1,337 | 3.4 | 3.2 | 2,349 |
| decreased appetiteSignal | 381 | 3.3 | 3.0 | 615 |
| vomitingSignal | 768 | 3.3 | 3.1 | 1,247 |
| pneumoniaSignal | 376 | 2.3 | 2.1 | 290 |
| diarrhoeaSignal | 728 | 2.3 | 2.1 | 532 |
| dyspnoeaSignal | 605 | 2.2 | 2.0 | 381 |
| fatigue | 570 | 1.5 | 1.4 | 89 |
| death | 611 | 1.4 | 1.3 | 81 |
| off label use | 461 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.